we will now have 7 phase 3s with REG1
bax855, 102bc-oc, 061, cirpo, levadex, 118, REG1,.............
levadex nda q4 2013 decision REG1 went thru ind, phase 1,2a,2b .
REG1: Regado’s lead candidate, the REG1 Anticoagulation System, is a two-component system comprising a Factor IXa inhibitor anticoagulant and its specific active control agent. REG1 is being developed for use in patients suffering from acute coronary syndrome (ACS), including those who undergo coronary revascularization procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). These procedures put patients at risk for therapy-related bleeding complications. REG1 is designed to increase therapeutic flexibility while reducing side effects and improving outcomes experienced by patients in this setting